Industry News
Broaden your audience, analyst tells biotechs
Biotechnology companies need to widen the audiences they pitch their messages to, industry analyst David Blake, of BioShares, told attendees at a BioMelbourne Network breakfast meeting today. [ + ]
Eiffel nets $2.2m Start grant
Melbourne drug re-engineering company Eiffel Technologies Ltd (ASX:EIF) has received a pleasant surprise from the Federal Government: a $2.2 million R&D Start grant. [ + ]
Imugene toasts future after formative year
Despite a decrease in revenues and an increase in net loss to AUD$1.3 million, veterinary biotechnology company Imugene (ASX:IMU) has come a long way in its first year as a biotechnology company, according to chairman Graham Dowland, who said it was a "tremendous formative year." [ + ]
Brutal honesty marks Iatia's response to a tough 12 months
Microscopy company Iatia (ASX:IAT) released its annual results last Friday with a brutally honest assessment of their performance over the 2002-2003 year. [ + ]
Peplin spruiks promising new compound
Brisbane's Peplin Biotech Ltd (ASX:PEP) has had a good week, reporting a promising new indication for its lead anti-cancer compound PEP005, and promising activity from a new compound of undisclosed provenance. [ + ]
BresaGen results sweetened by new ADR status
Adelaide-based biotechnology company BresaGen Ltd (ASX:BGN) has confirmed a consolidated loss for 2002-03 AUD$13.95 million, which it flagged last month, up from $11.86 million in 2002. [ + ]
New firm spruiks S Korea as manufacturing hub
Founded as a joint venture between Californian AIDS vaccine company VaxGen and South Korean investors, manufacturing company Celltrion is being developed to provide large-scale mammalian cell culture manufacturing for the biopharmaceutical industry. [ + ]
Monash researchers claim key MS find
Monash University researchers have solved the crystal structure of the protein suspected to be the focus of the autoimmune attack that destroys the fatty insulating sheath around neurons in the brain in multiple sclerosis (MS). [ + ]
Major new alliance for oil and gas research
Three of Western Australia's major research institutions have formed a united energy research partnership intended to benefit the operations of the global oil and gas industry with leading-edge practical research.
[ + ]New way to catch drug cheats in sport
The use of performance-enhancing drugs in sports continues to be a source of serious concern for both national and international sports organisations.
[ + ]Protein that fights brain disease and damage
A team of researchers from Imperial College London, the Charing Cross Hospital and University College London have identified a protein that they believe could be used to protect against neuro-degenerative conditions such as Alzheimer's, Parkinson's, Huntington's, motor neurone diseases and the brain damage caused by strokes.
[ + ]'Magic' potions for a greener environment
By mixing two solids, chemists can - as if by magic - create a liquid that is non-toxic and biodegradable: yet it can dissolve a range of materials. They have produced a series of such liquids that can be used to substitute the strong and corrosive acids traditionally used as solvents in many industrial chemical reactions.
[ + ]MS protein offers hope for new generation of drugs
Monash University researchers, using synchrotron radiation, have unravelled the structure of a protein that plays a crucial role in multiple sclerosis (MS), a finding that could eventually lead to the development of better drugs for treating this disease.
[ + ]pSivida subsid plans UK listing
Perth-based nanotechnology company pSivida plans to list its UK subsidiary pSiMedica next year. [ + ]
Viroids offer new gene-silencing possibilities
They're not life as we know it, not even life at all. A viroid is just a naked, sub-microscopic loop of single-stranded RNA -- a virus in the buff. But despite their simplicity, viroids possess a primeval weapon that can devastate crops- a weapon that of recent and great interest to molecular biologists. [ + ]